Endologix to Participate in Two Investor Conferences in March
IRVINE, Calif. -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chairman and Chief Executive Officer, and Shelley Thunen, Chief Financial Officer, are scheduled to participate at two investor conferences in March. The first conference is the 26th Annual ROTH Conference in Dana Point, CA.Event: 26th Annual ROTH Conference
Date: Monday, March 10, 2014
Time: 3:30 p.m. PT / 6:30 p.m.
ETEndologix Participants: John McDermott and Shelley Thunen
The second conference is the BTIG Inaugural Snowbird Medical Technology, Diagnostics, and Healthcare IT Conference in Snowbird, UT. This conference will allow institutional investors to meet with the Company but does not include a formal presentation.Event: BTIG Inaugural Snowbird Medical Technology, Diagnostics, and Healthcare IT Conference
Date: March 18-19, 2014
Endologix Participant: Shelley Thunen
An audio webcast of the Company’s presentation at the 26th Annual ROTH Conference will be available by visiting the investor relations section of Endologix’s website at www.endologix.com. A replay of the presentation will be available for 30 days.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. Endologix focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix’s website at www.endologix.com.
This news content was configured by WebWire editorial staff. Linking is permitted.